Advances in PH Journal
Prognostication and Risk Prediction for Pulmonary Hypertension 2015 (Vol 14, No 1)
- 2015 (Vol 14, No 1): Table of Contents
- Editor's Memo
It is my honor and pleasure to serve as Editor-in-Chief for Advances in Pulmonary Hypertension volumes 14 and 15.
- Guest Editors' Memo
This issue of Advances focuses on these specific tools, which include echocardiography, exercise, and biomarkers, as well as various risk prediction models derived from a number of databases.
- Rare Coexistence of Major Lung Pathologies
A 40-year-old African American female with past history of congenital heart murmurs of unknown etiology, iron deficiency anemia, and intellectual disability secondary to newborn shaken baby syndrome presented to the emergency department with worsening dyspnea, cough, sore throat, and fatigue.
- Vasoreactivity in PAH
Within the category of idiopathic pulmonary arterial hypertension (IPAH) is a subset of patients who express pulmonary vasoreactivity when challenged at the time of diagnosis with one of several drugs that produce acute vasodilatation.
- Circulating Biomarkers in Pulmonary Arterial Hypertension
Pulmonary arterial hypertension (PAH) is a progressive disease of the pulmonary vasculature that leads to exercise limitation, right heart failure, and death. There is a
need for biomarkers that can aid in early detection, disease surveillance, and
treatment monitoring in PAH.
- Consensus or Controversy: Do Recent Advances Shift the Debate for the Use of Echocardiography Versus Cardiac Magnetic Resonance Imaging of the Right Ventricle in Pulmonary Arterial Hypertension?
Pulmonary arterial hypertension (PAH) is a progressive, often lethal condition originating in the pulmonary arteriolar tree. It is typically manifested in stereotypical changes in the right ventricle (RV).
- Prognostication in Pulmonary Arterial Hypertension and Use of Current Risk Prediction Models
Significant therapeutic advances in the field of pulmonary arterial hypertension (PAH), increased awareness and diagnosis, and changing patient demographics in the contemporary era have facilitated the development of better prognostic tools for predicting survival.
- What Is the Utility of Evaluating Patients for Exercise-Induced Pulmonary Hypertension?
EXERCISE-INDUCED PULMONARY HYPERTENSION. Pulmonary hypertension (PH) is currently defined by a resting mean pulmonary artery pressure (mPAP) that is = 25 mm Hg.
- Pulmonary Hypertension Roundtable: Prognostic Indicators for Pulmonary Hypertension
Advances in Pulmonary Hypertension editor-in-chief Charles Burger, MD, Professor of Medicine at Mayo Clinic College of Medicine and Medical Director, PH Clinic, Mayo Clinic, Jacksonville, Florida, convened this issue’s guest editors Ioana Preston, MD, Co-director, Pulmonary Hypertension Center, Tufts Medical Center, Boston, and Raymond Benza, MD, Program Director, Heart Failure, Transplant, Mechanical Circulatory Devices and Pulmonary Hypertension, Western Pennsylvania Allegheny Health System, and Professor of Medicine, Temple University, Pittsburgh, along with editorial board member Jonathan Rich, MD, Assistant Professor of Medicine, Northwestern University Feinberg School of Medicine, Medical Director, Mechanical Circulatory Support Program, Bluhm Cardiovascular Institute, Northwestern Memorial Hospital, Chicago, for a wide-ranging discussion about clinicians’ ability to prognosticate about patients’ disease.
- PHPN: Holistic Assessment of the New Patient With Pulmonary Hypertension: The Role of the Non-Physician Clinician
Pulmonary hypertension (PH) does not discriminate based on social support, health literacy, emotional bandwidth, or socioeconomic status. Evaluating these factors provides an elemental foundation to best foster the patient’s adherence and success. The non-physician clinician plays a pivotal role in assessment of the new patient.